Schedule-dependent Therapeutic Effects of Gemcitabine Combined with Uracil-Tegafur in a Human Pancreatic Cancer Xenograft Model-Reference-Cited by-同舟云学术

Schedule-dependent Therapeutic Effects of Gemcitabine Combined with Uracil-Tegafur in a Human Pancreatic Cancer Xenograft Model

Published:2006-08 Issue:2 Volume:33 Page:142-147
ISSN:0885-3177
Container-title:Pancreas
language:en
Short-container-title:

Author:

Tsujie Masanori,Nakamori Shoji,Nakahira Shin,Takeda Setsuo,Takahashi Yuji,Hayashi Nobuyasu,Okami Jiro,Nagano Hiroaki,Dono Keizo,Umeshita Koji,Sakon Masato,Monden Morito

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference28 articles.

1. Pancreatic cancer.;Li;Lancet,2004

2. 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.;J Clin Oncol,1997

3. Advanced pancreatic cancer: is there a role for combination therapy?;Kulke;Expert Rev Anticancer Ther,2003

4. Systemic therapy for advanced pancreatic cancer.;El-Rayes;Expert Rev Anticancer Ther,2002

5. Action of 2, 2-difluorodeoxycytidine on DNA synthesis.;Huang;Cancer Res,1991

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon;Cancer Chemotherapy and Pharmacology;2021-07-31

2. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment;Molecular Pharmaceutics;2015-08-25

3. Membrane Drug Transporters and Chemoresistance in Human Pancreatic Carcinoma;Cancers;2010-12-30

4. Interdependence of Gemcitabine Treatment, Transporter Expression, and Resistance in Human Pancreatic Carcinoma Cells;NEOPLASIA;2010

5. Experimental study of combination therapy with S-1 against pancreatic cancer;Cancer Chemotherapy and Pharmacology;2009-04-01